Cancer Blood Test Fails to Catch Disease Earlier in Major Study

Follow Drugslib on

By I. Edwards HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 23, 2026.

via HealthDay

MONDAY, Feb. 23, 2026 — A blood test designed to find cancer early did not work as hoped in a major new study, according to the company that makes it.

The test, called Galleri, failed to lower the number of people diagnosed with late-stage cancer, its maker Grail announced last week.

The results are a blow to a fast-growing field that aims to catch cancer earlier, when treatment may be easier and more effective.

Galleri looks for tiny shards of cancer DNA in the blood and for more than 50 types of cancer.

The test has been sold in the U.S. since 2021, even though it has not been approved by the U.S. Food and Drug Administration (FDA). It costs $949, and most people pay for it out of pocket.

Grail says it has sold nearly 500,000 tests, including more than 185,000 last year alone.

The study followed 142,000 healthy adults ages 50 to 77 in Britain for three years. It was run with the U.K.’s National Health Service.

Some participants received the Galleri blood test. Others did not. Researchers hoped the test would find cancer earlier, at Stages 1 or 2, instead of later, when the disease is harder to treat.

That did not happen.

There was not a significant reduction in number of cancers diagnosed at Stage 3 or Stage 4, Grail said. The study’s main goal was to show a 20% drop in advanced cancers, but that target was missed.

“This doesn’t support rollout within the American health care system,” Dr. Richard Houlston, a cancer genetics expert at the Institute of Cancer Research, told The New York Times.

Grail executives said they were still encouraged by some results. They pointed to a drop in Stage 4 cancers and a rise in Stage 3 cases, which could mean cancers were found slightly earlier.

“It’s absolutely right to say we didn’t hit the primary endpoint,” said Harpal Kumar, Grail’s chief scientific officer. “But what we did see was a very compelling clinical benefit here.”

Other experts? They weren't convinced.

The study failed — "end of story," Dr. Adewole Adamson, a cancer researcher at the University of Texas at Austin, said.

“If there was a slam dunk result, we would have seen it,” he added.

Some cancers already have reliable screening tests, like mammograms and colonoscopies. But many deadly cancers do not, which is why Galleri raised so much hope.

Still, experts emphasized that finding cancer earlier does not always mean people live longer. In addition, blood tests can also miss cancers or raise false alarms.

“You’ve got this thing hanging over your head, but you don’t know what to do about it,” said Dr. Daniel Hayes of the Rogel Cancer Center in Ann Arbor, Michigan. He described cases where a blood test suggests cancer but scans find nothing.

A new law allows Medicare to cover some cancer detection tests, but Galleri is not automatically covered. Grail has also applied for FDA approval.

Experts say the failed trial could make that approval more difficult.

These results "are really sobering for this field,” Adamson added.

After the announcement, Grail’s stock dropped about 50%. Nearly all of the company’s revenue comes from Galleri sales.

Sources

  • The New York Times, Feb. 20, 2026

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2026-02-24 09:41

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords